Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01781299 · ClinicalTrials.gov registry record · Phase 4
Acellular Dermal Matrix in Tissue Expander Breast Reconstruction: A Prospective, Randomized, Clinical Trial Comparing SurgiMend PRS and AlloDerm RTU
A Phase 4 study, sponsored by University of Pittsburgh.
- Completed
- Registry status
- Phase 4
- Development phase
- 9
- Enrollment target
NCT01781299 is a Phase 4 study that has completed, run by University of Pittsburgh. The registered enrollment target is 9 participants.
The verdict
NCT01781299, a Phase 4 study, has completed, sponsored by University of Pittsburgh.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 9 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the relative performance and complication rates between the AlloDerm RTU and SurgiMend PRS products as well as the relative economics of these two treatment options.
Interventions
- DEVICE AlloDerm RTU
- DEVICE SurgiMend PRS
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2012-09 |
| Est. Completion | 2015-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01781299
The ClinicalTrials.gov registry entry for NCT01781299 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pittsburgh, which has 1,238 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which AlloDerm RTU is the first listed.
NCT01781299 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01781299 about?
NCT01781299 is a clinical study titled "Acellular Dermal Matrix in Tissue Expander Breast Reconstruction: A Prospective, Randomized, Clinical Trial Comparing SurgiMend PRS and AlloDerm RTU". The purpose of this study is to assess the relative performance and complication rates between the AlloDerm RTU and SurgiMend PRS products as well as the relative economics of these two treatment options.
What is the current status of trial NCT01781299?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 9 participants. The study started on 2012-09. Estimated completion is 2015-09.
What interventions are being tested in trial NCT01781299?
The interventions under investigation include: AlloDerm RTU (DEVICE), SurgiMend PRS (DEVICE).
Who is sponsoring clinical trial NCT01781299?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.